101results about How to "Promote clinical translation" patented technology

The invention provides camptothecin-adriamycin prodrug. A structural formula of the prodrug is shown as a formula (I), wherein R1 is camptothecin or derivative group thereof, R2 is one of -CH2- or -O-, R3 is one of -CH2- or -O-, X is one of S or -CH2-, and n1 and n2 are numbers of repeated units, and are integers from 0 to 10. The prodrug can be easily wrapped by amphiphilic polymer to form nanoparticles. The nanoparticles are high in drug carrying efficiency and drug carrying capacity and capable of quickly releasing unmodified camptothecin and adriamycin in the presence of glutathione, and the nanoparticles can be effectively taken in by tumor cells to kill the same. The invention further provides a preparation method of the prodrug, a preparation of the prodrug and application of the prodrug in preparing cancer treating drug.

The invention discloses a method for separation and in-vitro culture of pancreatic cancer tissue organs of human. The method comprises the following steps that (1) after the pancreatic cancer tissue of human is cut, enzymic digestion is repeatedly carried out for 10-20 minutes at 37 DEG C in a rotation speed of 30-40 rpm three times, and a pancreatic cancer single cell is obtained; (2) the pancreatic cancer single cell and matrigel are uniformly mixed, then a culture medium containing a growth factor PEG2 and gastrin I are added for culture, and the pancreatic cancer tissue organs of human areobtained. The method for separation and in-vitro culture of the pancreatic cancer tissue organs of human has the advantages that the tumor tissue is digested by adopting a short-time repeated digestion method, which can effectively improve the cell yield and cell viability; the culture medium containing the growth factor PEG2 and the gastrin I is adopted for culture, which can effectively promotethe growth of the pancreatic cancer organs and increase the survival rate of the pancreatic cancer organs.

The invention discloses a brain-computer interface system based on clinic brain-electrical signal control machine hand movement. The brain-computer interface system comprises a signal collection module, a brain-electrical signal feature extraction and decoding module, a machine hand control module and a peripheral module, wherein the signal collection module is used for pretreating collected clinic brain-electrical signals and inputting the pretreated signals into the brain-electrical signal feature extraction and decoding module; the brain-electrical signal feature extraction and decoding module is used for extracting the features of the pretreated brain-electrical signals; the machine hand control module is used for classifying the features of the pretreated brain-electrical signals and sending classification labels to machine hands to complete gesture movement; and the peripheral module is used for supervising and feeding back a task executed by the machine hands. The invention also discloses an application method of the brain-computer interface system. High-precision online machine hand gesture control can be realized by utilizing the clinic cortical brain-electrical signals with relatively high temporal-spatial resolution and small invasion degree.

The invention discloses a tumor-associated antigen XAGE-1b short-peptide and application thereof. The sequences of the short-peptide is one of the SEQ ID NO:2-SEQ ID NO:15. The CTL induced by the XAGE-1b antigen peptide does not produce an immune response to testicular cells, and only kills tumor cells. The obtained CTL clone has a good specific killing effect on tumor cells. The selected XAGE-1b antigen peptide has comparable affinity to HLA on DC cells and can effectively stimulate and induce specific CTLs, indicating that the selected XAGE-1b antigen peptide has good potential of polypeptide vaccine and DC vaccine. By cloning XAGE-1b antigen peptide specific TCR gene, constructing viral vector, transducing peripheral circulation CD8+T cells, TCR gene modified T cells (TCR-T) clone is obtained, and also has specific killing effect on tumor cells which is similar to parental CTL, suggesting that the XAGE-1b short-peptide has good clinical application and transformation prospect.

The invention relates to a multi-mode targeted probe for early hepatic fibrosis diagnosis and a preparation method thereof. The multi-mode targeted probe for the early hepatic fibrosis diagnosis is characterized by comprising a vector, and the vector is connected with a fluorescence group and a magnetic resonance imaging group and can be connected with a targeted compound group, which can be combined with a receptor on the surface of a hepatic stellate cell in hepatic fibrosis / cirrhosis, through a bridging group. The preparation method comprises the steps of: connecting the targeted compound group, which can be combined with the receptor on the surface of the hepatic stellate cell in the hepatic fibrosis / cirrhosis, with the bridging group, and sequentially connecting the targeted compoundgroup, the fluorescence group and the magnetic resonance imaging group on the vector. The targeted probe has higher sensitivity when being used for diagnosing and evaluating the fibrosis diagnosis.

The invention provides a culture solution for retinal pigment epitheliums (hESC-RPE). The culture solution is characterized in that the culture solution contains, 96-97.5 volume fractions of a basic culture medium, 1 volume fraction of non-essential amino acids (NEAA), 1 volume fraction of L-glutamine, 0.5-21 volume fractions of an N2 additive, a component a and a component b. The invention further provides a preparation method of the culture solution and a method for culturing the retinal pigment epitheliums (hESC-RPE) by using the culture solution. Compared with existing culture media, the culture medium of the culture solution is simple composition, the costs are lower, no ethical problem is related, and cell proliferation can be promoted.

The invention discloses a drug-loaded microsphere and a preparation method thereof. The drug-loaded microsphere comprises nanoparticles containing active pharmaceutical ingredients and a framework material for wrapping a drug and controlling drug release, wherein the mass of the active pharmaceutical ingredients accounts for 1-80% of the mass of the whole microsphere; the encapsulation efficiency of the active pharmaceutical ingredients in the encapsulation process is 50-100%; and the particle size of the microspheres is 0.5-2000 [mu] m. The preparation method comprises the steps of precipitating the active pharmaceutical ingredients to form drug nanoparticles; then dispersing the drug nanoparticles in an oil phase to prepare an oil-in-water emulsion; and curing the oil-in-water type emulsion to form microspheres. The microspheres are relatively high in encapsulation efficiency and drug loading capacity, the treatment efficiency is improved, and extremely high application value is achieved.

The invention discloses a tumor-associated antigen XAGE-1b short peptide and an application thereof. The sequence of the short peptide is selected from SEQ ID NO: 2-SEQ ID NO: 13. Cytotoxic T lymphocytes (CTLs) induced by the XAGE-1b antigen peptides do not generate immune response to testicular cells, and only kill tumor cell. The induced CTL clones have good tumor cell specific killing effect. Meanwhile, in the process of establishing the CTLs, the screened XAGE-1b antigen peptides are found to have appropriate affinity with HLA on DC cells and can effectively stimulate and induce the generation of specific CTLs, and it is proved that the XAGE-1b antigen peptides have good potential of a polypeptide vaccine and a DC vaccine. XAGE-1 b antigen peptide specific TCR genes are cloned, a virus carrier is constructed, the genes are transduced to CD8+T cells from peripheral circulation to obtain TCR gene modified T cell (TCR-T) clones, and also the specific killing effect on tumor cells similar to parental CTLs is obtained, and thus the tumor-associated antigen XAGE-1b short peptide has good clinical conversion and practical application prospect.

The invention belongs to the fields of genetic engineering and oncology and discloses an internal reference for detecting miRNA (micro Ribonucleic Acid) in serum / blood plasma and application of the internal reference. The internal reference is separate miR-484 or miR-191 or a combination of the miR-191 and the miR-484. The internal reference and a primer of the internal reference can be used for preparing an internal reference detection kit which is used for detecting the internal reference of the miRNA in serum / blood plasma.

The invention discloses an antimicrobial peptide. An amino acid sequence thereof is shown as any one of SEQ ID NO:1-SEQ ID NO:7. The antimicrobial peptide disclosed by the invention is capable of moreefficiently restraining activity of streptococcus mutans under floating state and biofilm state; the antimicrobial peptide has a rapid sterilizing effect, low cytotoxicity and high antibiofilm activity; the antimicrobial peptide has the advantages of simple synthesis and low production cost; the antimicrobial peptide is suitable for mass synthesis and is beneficial to clinical conversion.

The invention discloses a composite amphipathic peptide nano-micelle and a preparation method and applications thereof, and particularly relates to a novel composite amphipathic peptide nano-micelle targeting integrin alpha<v>beta<3>, and applications thereof in breast cancer fluorescence imaging, photodynamic therapy and photothermal therapy. Based on the good biocompatibility of the targeted amphipathic peptide nano-micelle, the fluorescence imaging of encapsulating materials and the photodynamic therapy and photothermal therapy functions, the nano-micelle is expected to be widely used in the fields of marker and tracer in vivo, biomedical imaging and early diagnosis and treatment of tumors, and to produce good economic and social benefits in terms of life health and personalized medicine.

The invention discloses a flexible micro-column ring array for detecting the contractility of a clot and a preparation method and application of the flexible micro-column ring array. The micro-columnring array is composed of a plurality of micro-column rows arranged periodically, each micro-column row is provided with a plurality of micro-column rings, and each micro-column ring is composed of four or more micro-columns forming a ring shape in a surrounding mode, wherein a circular pore with a certain diameter is formed in the micro-column ring, and when the contractility of the clot is detected, whole blood is dropped into the circular pore of the micro-column ring for blood coagulation detection. According to the invention, a whole blood sample is efficiently fixed in the micro-column ring by utilizing the interfacial tension of a solid-liquid-gas system and the resistance of the micro-column; meanwhile, the micro-column is used as a force sensor to measure the contraction force ofa clot in real time, the detection result is high in sensitivity and low in detection cost, and clinical transformation is easy; besides, platelets do not need to be separated from blood, whole bloodcan be used for detection, the influence of other components in the blood on platelet contraction is fully considered, and the result is more objective and comprehensive.

The invention discloses a bone implant material based on nano-enzyme modification and a preparation method and application thereof. The bone implant material based on nano-enzyme modification is obtained by modifying a bone implant material with nano-enzyme or a precursor of the nano-enzyme (the nano-enzyme can be prepared in situ), and the bone implant material, as an efficient orthopedic treatment mode, is directly related to the therapeutic effect due to the influence and regulation effect on the metabolic balance of bone tissues. According to the invention, the ROS elimination capability and ALP hydrolytic activity of the nano-enzyme in a specific environment are utilized to enhance the osseointegration capability and osteolysis inhibition effect of the bone implant material; in addition, bacterial adhesion or growth is inhibited by using the ROS generation capability and the multi-hydrolytic activity of the nano-enzyme, and bacterial biofilms are destroyed to enhance an anti-infection effect of combined antibiotics at the same time. By means of an efficient complementary design, the invention has therapeutic characteristics in multiple aspects, and bone metabolism imbalance diseases related to the bone implant material can be treated, relieved and / or prevented.

The invention discloses a novel human CD38 specific single-domain antibody and a coding gene thereof, prepares a novel molecular imaging probe for diagnosing multiple myeloma, and relates to the fieldof nuclear medicine and molecular imaging. The probe comprises a tumor targeting group, a chelating agent and radionuclide. According to the probe, the non-invasive visualization of human CD38 molecular expression is achieved, the non-invasive diagnosis of multiple myeloma and lymphoma is achieved, and the probe has the advantages of being simple in preparation process, low in cost, high in specificity, high in stability, short in imaging period, low in radiation dose, easy to convert clinically and the like.

The invention belongs to the technical field of medical imaging, and discloses a Cherenkov endoscope system based on conical optical fiber connection and a medical imaging system. The Cherenkov endoscope system comprises an endoscope probe, an optical fiber image-transmitting bundle, a connecting device, a detecting device and a computing and imaging device, wherein the connecting device is a conical optical fiber and is used for connecting an endoscope with an imaging camera. The conical optical fiber is used as the connecting device for the endoscope and the imaging camera, and therefore theoptical signal loss of the Cherenkov endoscope system is effectively reduced; the Cherenkov endoscope system is simple in structure and meets clinical application requirements. The collecting rate ofCherenkov optical signals is high; the conical optical fiber is used for replacing an medical endoscope adapter to connect the optical fiber image-transmitting bundle and the imaging camera, a metalprotective bush completely wraps the conical optical fiber, in this way, the optical signal loss caused by the adapter and a coupling part is substantially reduced, the signal collection time for effective imaging of the Cherenkov endoscope is shortened, and clinical conversion of the Cherenkov endoscope is promoted.

The invention discloses a high-molecular MRI contrast agent based on lysine. The contrast agent has a structure shown as a formula I, wherein n represents an integer between 10-100. The high-molecular MRI contrast agent has simple structure, good biocompatibility, no toxic or side effect, easiness for clinic conversion, relaxation rate of 7.32 mM<-1>.s<-1>, which is obviously higher than that of a micro-molecular contrast agent, and better MRI radiography effect. The invention also discloses a preparation method of the high-molecular MRI contrast agent based on lysine. An amino acid of lysine required by human body is used as a unit for constructing the high-molecular agent; and esterification derivatives of lysine and diethylene triamine pentacetic acid dianhydride are subjected to polycondensation, hydrolysis and gadolinium chelating to obtain the high-molecular MRI contrast agent. The preparation method is simple, easy to control and suitable for industrialized large-scale production.

The invention relates to a method for inducing stem cells into liver cells and a kit. Particularly, the invention relates to the kit which has clear chemical ingredients, and comprises a second culture medium and / or a third culture medium; and optionally, the kit further comprises a first culture medium. A culture system provided by the invention is simple in formula and clear in ingredients, doesnot contain animal derived ingredients and does not involve any ethical issue; and the induction efficiency can be improved, and the system has a very high clinical application prospect.

The invention relates to a preparation method of hollow vesicular manganous silicate nanoparticles with stable arginine, a product and an application thereof. The preparation method comprises the following steps: 1) dissolving arginine in water, adding cyclohexane and mixing the materials, heating a mixture, then adding ethyl orthosilicate for a reaction, after the reaction is completed, removing cyclohexane to obtain the silica nanoparticles with stable arginine; and 2) mixing the silica nanoparticles, potassium permanganate, ethanol and water and performing a hydro-thermal reaction, and separating the mixture to obtain the hollow vesicular manganous silicate nanoparticles. The prepared hollow vesicular manganous silicate nanoparticles with stable arginine can generate good T1 imaging effect during a magnetic resonance imaging process.

The invention discloses a self-assembled nano-drug of a single drug of molecular targeted drugs, a co-assembled nano-drug of molecular targeted drugs and other hydrophobic drugs, a preparation methodand an application thereof. Meanwhile, all drugs used have been approved by the US FDA for market use and have good application prospects. The nanoparticle is formed by single-drug self-assembly of molecular targeted drugs, multi-drug co-assembly of molecular targeted drugs and hydrophobic drugs, does not need an additional carrier, has a passive targeting effect, and is easy to stay at a tumor site through an EPR effect, so that the toxic and side effects of the drugs on normal tissues are greatly reduced.

The invention provides a construction method of a mouse ischemic stroke model. According to the construction method, current stimulation is given to a Common carotid artery (CCA) of a mouse to form a thrombus embolus, the thrombus embolus is activated, the thrombus embolus is made to spontaneously enter the cranium through an Internal carotid artery (ICA), the intracranial Middle artery (MCA) is blocked, and then acute brain blood supply blocking and brain dysfunction are caused. The invention also provides an evaluation method of the mouse ischemic stroke model. The evaluation method comprises the following steps: marking the thrombus embolus formed on the CCA by using a near-infrared fluorescent molecular probe, tracking the position of the thrombus embolus in the mouse cranium by using a small animal living imaging instrument, and evaluating the ICA clogging degree by using fluorescence intensity.

The invention belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, relates to taxane drug and doxorubicin prodrug self-assembled nanoparticles and application thereof, and in particular relates to synthesis of a redox sensitive taxane drug and doxorubicin prodrug with tumour tissue specific response, preparation of the taxane drug and doxorubicin prodrug self-assembled nanoparticles and application of the taxane drug and doxorubicin prodrug self-assembled nanoparticles in a drug delivery system. The taxane drug and doxorubicin prodrug in the invention comprises a taxane drug and doxorubicin prodrug connected with a carbon chain and a taxane drug and doxorubicin prodrug connected with a redox sensitive thioether bond; and the structural general formula of the taxane drug and doxorubicin prodrug is shown in the specification, wherein R<1>, R<2>, X, Y, Z, n<1> and n<2> are described in the claims and the specification.

The invention discloses a visual fluorescent fiber as well as a preparation method and application thereof. The visual fluorescent fiber comprises a core layer fiber doped with a fluorescent material and a shell layer coating the core layer fiber, and at least the surface of the outermost shell layer is hydrophobic. The visual fluorescent fiber provided by the invention has the advantages of high brightness, good hydrophobicity, high stability, mechanical property, controllable diameter and the like, the preparation process is simple, the reaction condition is mild, large-scale production can be realized, the fluorescent fiber is expected to provide a simpler, more accurate, quicker and safer tube penetrating method for 360-degree viscous tubule operation, the operation success rate is increased, the method has an extremely high clinical application prospect, and meanwhile, a new research thought is provided for 360-degree viscocanlostomy and glaucoma treatment.

The invention discloses a tumor associated antigen XAGE-1b short peptide and application thereof. The sequence of the short peptide is one of SEQ ID NO:2-SEQ ID NO:15. CTL established by induction of XAGE-1b antigen peptide cannot generate an immunologic response to testis cells and only kills tumor cells. CTL clone obtained by induction has a favorable specific tumor cell killing effect; meanwhile, during a CTL establishment process, the inventor discovers that the screened XAGE-1b antigen peptide has appropriate appetency with HLA on DC cells and is capable of effectively stimulating and inducing production of specific CTLs, which indicates that the XAGE-1b antigen peptide has favorable polypeptide vaccine and DC vaccine potentials. By virtue of cloning the specific TCR genes of the XAGE-1b antigen peptide, a virus carrier is established, peripheral circulation CD8+T cells are transduced, TCR gene modified T cell (TCR-T) clone is obtained and also has a similar specific tumor cell killing effect with the parent-generation CTL, which indicates that the TCR gene modified T cell clone has favorable clinical conversion and practical application prospects.

The invention relates to a composition for processing a biological sample. The composition for processing the biological sample is composed of pharmaceutically acceptable hydroxyethyl starch, a pharmaceutically acceptable ionic iodine contrast agent, an osmotic pressure regulator and a pH value modifier according to the mass ratio of (2.0-12.0):(2.5-12.0):(0-0.4):(0-0.5). A part of parameters exceed the traditional commercially available similar products at home and abroad when the composition provided by the invention is applied to gathering a mononuclear cell and the like in the biological sample. Thus, the composition has higher safety and validity, and the possibility is created for clinical translation of the products.

The invention provides a solubilizing BODIPY photosensitizer and a preparation method and application thereof in preparing medicine for treating body surface diseases, and belongs to the field of medicine and medical methods. The photosensitizer is obtained by dissolving fat-soluble BODIPY or aza-BODIPY in an organic solvent and achieving solubilization by conversion from an organic solution to awater system. The preparation method of the solubilizing BODIPY photosensitizer and the application of the solubilizing BODIPY photosensitizer in preparing the medicine for treating the body surface diseases are also provided. The BODIPY photosensitizer prepared by the preparation method can be applied at a lower drug concentration and dosage, the light intensity required for photoexcitation is about 10-100 mW / cm<2>, the illumination time is 10-30 minutes, the total excitation energy is about 10-180 J / cm<2>, and the tolerance and compliance of patients are significantly improved.

The invention discloses a triclosan-based nano antibiotic hydrogel TCS-GA-GFFY. By chemical bonding of TCS with self-assembled peptide, a polypeptide derivative TCS-GA-GFFY is prepared; and through the heating-cooling mode, TCS-GA-GFFY supramolecular hydrogel is formed and used as nano-antibiotic to enhance the effect of treating bacterial infection. The invention is characterized in that the preparation is simple, and the raw materials are easily available; and the product has good biocompatibility and is easy for clinical transformation. Meanwhile, the problem of poor water solubility of TCSis obviously improved, and the bioavailability of TCS is improved. Especially compared with free TCS, the TCS-GA-GFFY supramolecular hydrogel releases TCS through acid responsiveness and shows betterbacteria killing ability.

The invention discloses an Epstein-Barr (EB) virus related antigen short peptide and application thereof. The sequence of the EB virus related antigen short peptide is shown as any of SEQ ID NO:1-16;the short peptide has high affinity with MHC I-type and MHC II-type molecules on dendritic cells (DC), can effectively achieve the antigen presentation effect and has the good potential of a polypeptide vaccine and a DC vaccine; the DC vaccine prepared from the one or more in-vitro sensitized DCs in the short peptide can prevent EB virus related diseases, and thus the good clinical transformationprospects are achieved; and the antigen short peptide is small in length and small in chemical synthesis difficulty and can be directly synthesized to obtain a high-purity product, the application cost is lowered greatly, meanwhile the effect is clear, and the antigen short peptide has great application prospects.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a targeted drug delivery system, specifically to a platelet-like liposome drug delivery system, and a preparation method and an application thereof. The drug delivery system is prepared from a platelet membrane and a traditional liposome through extrusion membrane-filtering and fusing. The drug delivery system has the advantages of both natural targeting of a platelet and in-vivo long circulation of a lipidosome; in-vitro adhesion experiment results prove that the platelet-like lipidosome has the adhesion capacity similar to the adhesion capacity of a pure platelet vesicle to collagen and fibrinogen; in-vitro targeting experiment results prove that the platelet-like liposome has good targeting similar to the targeting of the pure platelet vesicle to tumor cells; pharmacokinetic experiment results prove that the platelet-like lipidosome has long in-vivo circulation time close to the in-vivo circulation time of a traditional lipidosome; and in-vivo targeting experiment results prove that the platelet-like lipidosome has a targeting effect significantly higher than the targeting effect of a traditional lipidosome and the pure platelet vesicle on residual tumors and metastatic tumors.

The invention relates to a nanoparticle preparation for treating HPV (Human Papilloma Virus) infection and a preparation method of the nanoparticle preparation. The nanoparticle preparation for treating the HPV infection is prepared from a poly(beta amino ester) polymer and a recombinant plasmid DNA (Deoxyribonucleic Acid) for knocking out or knocking down the HPV in a targeting manner. The nanoparticle preparation disclosed by the invention takes the poly (beta amino ester) polymer and the recombinant plasmid DNA for knocking out or knocking down the HPV in a targeting manner as main raw materials and has the advantages of good specificity, high transfection efficiency, low toxic or side effects and the like.

The invention relates to bimodal nanoprobes and a preparation method thereof, and application of the bimodal nanoprobes to image-guided brain tumor resection, belonging to the field of molecular imaging probes. The nanoprobes use a gold nanoparticle as a carrier; the surface of the gold nanoparticle is modified by a magnetic resonance imaging group Gd<3+>-DTPA, a Raman reporter molecule IR783B, acyclooctyne group DBCO or an azido group N=N=N, polyethylene glycol, and an across-blood-brain-barrier targeting group Angiopep-2; and the targeting group Angiopep-2 specificity guides the nanoprobesacross blood-brain barriers through transcytosis, and the nanoprobes form aggregate in the acidic environment of brain tumors, so magnetic resonance signals and Raman scattering signals are enhanced at the same time. The bimodal nanoprobes employ a bimodal image technology of combined surface-enhanced resonant Raman scattering and magnetic resonance imaging, can locate tumors through magnetic resonance imaging before an operation, and utilize surface-enhanced resonant Raman scattering imaging to guide tumor resection during the operation. The bimodal nanoprobes provided by the invention have important scientific research and clinical significance to improvement of therapeutic effect on brain tumors and promotion of the clinical and translational practice of individual-based treatment methods.